Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 2.24 Million AUD | 248.15% |
| 2023 | 644.42 Thousand AUD | 78.99% |
| 2022 | 360.03 Thousand AUD | -29.86% |
| 2021 | 513.28 Thousand AUD | 50.61% |
| 2020 | 340.8 Thousand AUD | 100.95% |
| 2019 | 169.6 Thousand AUD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 2.05 Million AUD | 471.22% |
| 2024 Q4 | 2.24 Million AUD | 0.0% |
| 2024 Q2 | 2.05 Million AUD | 0.0% |
| 2024 FY | 2.24 Million AUD | 248.15% |
| 2023 Q3 | 644.42 Thousand AUD | 14.65% |
| 2023 FY | 644.42 Thousand AUD | 78.99% |
| 2023 Q4 | 360.03 Thousand AUD | -44.13% |
| 2023 Q2 | 562.1 Thousand AUD | 0.0% |
| 2023 Q1 | 562.1 Thousand AUD | 56.13% |
| 2022 FY | 360.03 Thousand AUD | -29.86% |
| 2022 Q4 | 360.03 Thousand AUD | 0.0% |
| 2022 Q3 | 360.03 Thousand AUD | -17.25% |
| 2022 Q2 | 435.09 Thousand AUD | 0.0% |
| 2022 Q1 | 435.09 Thousand AUD | -15.23% |
| 2021 Q3 | 513.28 Thousand AUD | 0.0% |
| 2021 FY | 513.28 Thousand AUD | 50.61% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 Q4 | 513.28 Thousand AUD | 0.0% |
| 2020 FY | 340.8 Thousand AUD | 100.95% |
| 2019 FY | 169.6 Thousand AUD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Australian Clinical Labs Limited | 16.82 Million AUD | 86.666% |
| BCAL Diagnostics Limited | -2.69 Million AUD | 183.23% |
| Genetic Signatures Limited | 6.72 Million AUD | 66.619% |
| Genetic Technologies Limited | 206.46 Thousand AUD | -986.638% |
| Healius Limited | 31.9 Million AUD | 92.967% |
| Imagion Biosystems Limited | - AUD | -Infinity% |
| Integral Diagnostics Limited | 1.65 Million AUD | -35.891% |
| INOVIQ Ltd | 17.83 Thousand AUD | -12482.357% |
| Monash IVF Group Limited | 8.17 Million AUD | 72.566% |
| Rhythm Biosciences Limited | 57.77 Thousand AUD | -3783.339% |
| Sonic Healthcare Limited | 208.83 Million AUD | 98.926% |